Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma

Blood (2024) 144 (23): 2432–2438.

https://doi.org/10.1182/blood.2024024995

Published: 2024

Includes: Supplemental data

Journal Articles

Clinical Value of Peripheral Residual Disease (PRD) and Measurable Residual Disease (MRD) in Newly Diagnosed Elderly Patients in the GEM2017FIT Trial

Blood (2024) 144 (Supplement 1): 365.

https://doi.org/10.1182/blood-2024-209748

Published: 2024

Journal Articles

Unraveling Long-Term Survival of Multiple Myeloma Patients, the GEM2000 Experience

Blood (2024) 144 (Supplement 1): 1957.

https://doi.org/10.1182/blood-2024-211383

Published: 2024

Journal Articles

Reevaluating the IMWG Multiple Myeloma Complete Response Criterion in the Era of Mass Spectrometry: A Critical Analysis

Blood (2024) 144 (Supplement 1): 489.

https://doi.org/10.1182/blood-2024-210198

Published: 2024

Journal Articles

Measurable Residual Disease and Peripheral Residual Disease to Assess Treatment Response in Real-World Patients with Newly Diagnosed Multiple Myeloma

Noemi Puig, Panagiotis Malandrakis, Cristina Agullo, Sergio Castro, Teresa Contreras, Veronica Gonzalez-Calle, Beatriz Rey-Búa, Borja Puertas Martínez, Evangelos Terpos, Meletios A. Dimopoulos, Maria- Victoria Mateos, Efstathios Kastritis

Blood (2024) 144 (Supplement 1): 4694.

https://doi.org/10.1182/blood-2024-209661

Published: 2024

Journal Articles

Determining Outcome in IgM Gammopathies: Integration of Molecular, Flow Cytometry and Clinical Factors in an International, Multicenter Series (the SAL-TO Study)

Blood (2024) 144 (Supplement 1): 4390.

https://doi.org/10.1182/blood-2024-197940

Published: 2024

Journal Articles

Long-Term Effects of Belantamab Mafodotin Plus Bortezomib, Lenalidomide and Dexamethasone (VRd) on T Cell Exhaustion Phenotype

Mauro Lorenzo, Juan-José Garcés, Leire Burgos, Irene Manrique, Marta Lasa, Noemi Puig, Janet Sotolongo-Ravelo, Marta González-Rodríguez, Bárbara Castellanos, Maria Teresa Cedena Romero, Bruno Paiva, Veronica Gonzalez-Calle, Maria-Victoria Mateos, Mercedes Garayoa, Teresa Paíno

Blood (2024) 144 (Supplement 1): 6866.

https://doi.org/10.1182/blood-2024-209686

Published: 2024

Journal Articles

Clinical Significance of Measurable Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Chimeric Antigen Receptor (CAR) T Cells and T-Cell Engagers (TCE)

Aintzane Zabaleta, Noemi Puig, Maria Teresa Cedena Romero, Jose J Perez, Cristina Moreno, Luis-Esteban Tamariz-Amador, Paula Rodriguez Otero, Veronica Gonzalez-Calle, Lucia Lopez Corral, Beatriz Rey-Búa, Borja Puertas Martínez, Fatima Miras, Jose Sanchez-Pina, Nieves Lopez, Joaquin Martinez-Lopez, Maria Victoria Mateos, Jesus San-Miguel, Bruno Paiva

Blood (2023) 142 (Supplement 1): 94.

https://doi.org/10.1182/blood-2023-185980

Published: 2023

Journal Articles

Minimally Invasive Assessment of Measurable Residual Disease (MRD) in Multiple Myeloma (MM)

Blood (2023) 142 (Supplement 1): 339.

https://doi.org/10.1182/blood-2023-186916

Published: 2023

Journal Articles

Isolated and Dynamic Peripheral Blood Residual Disease Status Characterized By Mass Spectrometry Predicts Outcome in Patients with High Risk Smoldering Multiple Myeloma Treated in the GEM-CESAR Trial

Blood (2023) 142 (Supplement 1): 645.

https://doi.org/10.1182/blood-2023-182964

Published: 2023

Journal Articles

ARI0002h (Cesnicabtagene Autoleucel), an Academic Point-of-Care B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Strategy: Activity and Safety after Fractionated Initial Therapy and Booster Dose in 60 Patients with Relapsed/Refractory Multiple Myeloma

Blood (2023) 142 (Supplement 1): 1026.

https://doi.org/10.1182/blood-2023-180828

Published: 2023

Journal Articles

Renal Sub-Study (GEM-KyCyDex): Cystatin C Improves the Proficiency of Creatinine Alone in the Detection and Management of Myeloma-Related Renal Impairment

Javier Cepeda-Piorno, Borja Puertas Martínez, Laura Rosiñol, Albert Oriol, Felipe De Arriba, Luis Palomera, Miguel Teodoro Hernandez, Jaime Pérez De Oteyza, Ana Pilar Gonzalez, David Carballo, Veronica Gonzalez-Calle, Paula Chavez, Vanesa Garcia-Moreira, Enrique M Ocio, Maria Victoria Mateos, Esther Gonzalez Garcia

Blood (2023) 142 (Supplement 1): 4758.

https://doi.org/10.1182/blood-2023-185012

Published: 2023

Journal Articles

Lenalidomide maintenance based on a genetic profile

María-Victoria Mateos, Verónica González-Calle

Blood (2023) 141 (14): 1649–1650.

https://doi.org/10.1182/blood.2022019352

Published: 2023

Journal Articles

Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Included in the Compassionate Use or the Expanded Access Program. Experience with a Spanish Cohort

Blood (2022) 140 (Supplement 1): 4315–4317.

https://doi.org/10.1182/blood-2022-158538

Published: 2022

Journal Articles

Belantamab Mafodotin in Combination with Vrd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Results from the Phase II, Open Label, Multicenter, GEM-BELA-Vrd Trial

Blood (2022) 140 (Supplement 1): 7286–7288.

https://doi.org/10.1182/blood-2022-162584

Published: 2022

Journal Articles

Immune Biomarkers of Survival and Severe Infection in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with the Backbone Regimen Lenalidomide and Dexamethasone (Rd)

Catarina Maia, Noemi Puig, Cristina Pérez Ruiz, Maria Teresa Cedena Romero, Camila Guerrero, Marta Larrayoz, Cirino Botta, Norma C. Gutierrez, María José Calasanz, Maria Luisa Martin-Ramos, Miguel Hernández, Laura Rosinol Dachs, Esther González Garcia, Felipe De Arriba, Albert Oriol, Veronica Gonzalez-Calle, Fernando Escalante, Javier de la Rubia, Mercedes Gironella Mesa, Rafael Rios, Ricarda Belen Garcia Sanchez, Jose Maria Arguiñano PEREZ, Adrian Alegre, Jesus Martin, María del Carmen Couto Caro, Maria Casanova, Mario Arnao Herraiz, Ernesto Pérez, Sebastián Garzón López, Marta Sonia Gonzalez Perez, Guillermo Martín-Nuñez, Adriana Rossi, Morton Coleman, Cristina Encinas, Ana M. Vale, Ana Isabel Teruel, María Cortés Rodríguez, Jose A. Martinez-Climent, Juan-José Lahuerta, Joan Bladé Creixenti, Ruben Niesvizky, Jesús San-Miguel, Maria-Victoria Mateos, Bruno Paiva

Blood (2022) 140 (Supplement 1): 4200–4203.

https://doi.org/10.1182/blood-2022-163058

Published: 2022

Journal Articles

CAR-T Related Cytopenia Profile in Relapsed/Refractory Multiple Myeloma: Results of Patients Treated with ARI0002h, an Academic BCMA-Directed CAR-T Cell

Blood (2022) 140 (Supplement 1): 10347–10349.

https://doi.org/10.1182/blood-2022-166525

Published: 2022

Journal Articles

Clonal Architecture and Evolution of Waldenström's Macroglobulinemia at the Single Cell Level

Cristina Jiménez, María García-Álvarez, Miguel Alcoceba, Alejandro Medina, Elham Askari, Veronica Gonzalez-Calle, Maria Casanova, Fernando Escalante Barrigón, M Eugenia Sarasquete, Marcos González Díaz, María Carmen Chillón Santos, Ramón García-Sanz

Blood (2022) 140 (Supplement 1): 3510–3511.

https://doi.org/10.1182/blood-2022-163057

Published: 2022

Journal Articles

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)

Blood (2022) 140 (Supplement 1): 292–294.

https://doi.org/10.1182/blood-2022-159606

Published: 2022

Journal Articles

Correlative Biological Studies Related to the Response, Peak and Persistence of ARI0002h, an Academic BCMA-Directed CAR-T Cell, with Fractionated Initial Infusion and Booster Dose for Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Blood (2021) 138 (Supplement 1): 552.

https://doi.org/10.1182/blood-2021-148281

Published: 2021

NARROW

Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma

Clinical Value of Peripheral Residual Disease (PRD) and Measurable Residual Disease (MRD) in Newly Diagnosed Elderly Patients in the GEM2017FIT Trial

Unraveling Long-Term Survival of Multiple Myeloma Patients, the GEM2000 Experience

Reevaluating the IMWG Multiple Myeloma Complete Response Criterion in the Era of Mass Spectrometry: A Critical Analysis

Measurable Residual Disease and Peripheral Residual Disease to Assess Treatment Response in Real-World Patients with Newly Diagnosed Multiple Myeloma

Determining Outcome in IgM Gammopathies: Integration of Molecular, Flow Cytometry and Clinical Factors in an International, Multicenter Series (the SAL-TO Study)

Long-Term Effects of Belantamab Mafodotin Plus Bortezomib, Lenalidomide and Dexamethasone (VRd) on T Cell Exhaustion Phenotype

Clinical Significance of Measurable Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Chimeric Antigen Receptor (CAR) T Cells and T-Cell Engagers (TCE)

Minimally Invasive Assessment of Measurable Residual Disease (MRD) in Multiple Myeloma (MM)

Isolated and Dynamic Peripheral Blood Residual Disease Status Characterized By Mass Spectrometry Predicts Outcome in Patients with High Risk Smoldering Multiple Myeloma Treated in the GEM-CESAR Trial

ARI0002h (Cesnicabtagene Autoleucel), an Academic Point-of-Care B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Strategy: Activity and Safety after Fractionated Initial Therapy and Booster Dose in 60 Patients with Relapsed/Refractory Multiple Myeloma

Renal Sub-Study (GEM-KyCyDex): Cystatin C Improves the Proficiency of Creatinine Alone in the Detection and Management of Myeloma-Related Renal Impairment

Lenalidomide maintenance based on a genetic profile

Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Included in the Compassionate Use or the Expanded Access Program. Experience with a Spanish Cohort

Belantamab Mafodotin in Combination with Vrd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Results from the Phase II, Open Label, Multicenter, GEM-BELA-Vrd Trial

Immune Biomarkers of Survival and Severe Infection in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with the Backbone Regimen Lenalidomide and Dexamethasone (Rd)

CAR-T Related Cytopenia Profile in Relapsed/Refractory Multiple Myeloma: Results of Patients Treated with ARI0002h, an Academic BCMA-Directed CAR-T Cell

Clonal Architecture and Evolution of Waldenström's Macroglobulinemia at the Single Cell Level

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)

Correlative Biological Studies Related to the Response, Peak and Persistence of ARI0002h, an Academic BCMA-Directed CAR-T Cell, with Fractionated Initial Infusion and Booster Dose for Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only